AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 84 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $962,308 | -68.8% | 93,428 | -50.0% | 0.00% | -33.3% |
Q2 2023 | $3,082,090 | +17.6% | 187,020 | -34.6% | 0.00% | 0.0% |
Q1 2023 | $2,621,318 | +163.4% | 286,170 | +105.9% | 0.00% | 0.0% |
Q4 2022 | $995,276 | +24.9% | 139,005 | -12.6% | 0.00% | +50.0% |
Q3 2022 | $797,000 | +97.8% | 159,005 | -3.6% | 0.00% | +100.0% |
Q2 2022 | $403,000 | -44.3% | 165,005 | +55.6% | 0.00% | -50.0% |
Q1 2022 | $724,000 | -45.8% | 106,071 | -35.9% | 0.00% | -33.3% |
Q4 2021 | $1,336,000 | -17.5% | 165,355 | 0.0% | 0.00% | -25.0% |
Q3 2021 | $1,620,000 | +45.7% | 165,355 | 0.0% | 0.00% | +33.3% |
Q2 2021 | $1,112,000 | -25.6% | 165,355 | 0.0% | 0.00% | -25.0% |
Q1 2021 | $1,495,000 | +244.5% | 165,355 | +154.4% | 0.00% | +300.0% |
Q4 2020 | $434,000 | +32.3% | 65,005 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $328,000 | -71.1% | 65,005 | -56.7% | 0.00% | -75.0% |
Q4 2019 | $1,133,000 | +81.6% | 150,000 | 0.0% | 0.00% | +100.0% |
Q3 2019 | $624,000 | +43.8% | 150,000 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $434,000 | – | 150,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |